|
|
Post by letitride on Jan 1, 2021 17:55:31 GMT -5
You pay for a PRV to fill an unmet need with expediency. Que Martine.
Lets Go!
|
|
|
|
Post by harryx1 on Jan 22, 2021 10:45:03 GMT -5
|
|
|
|
Post by centralcoastinvestor on Jan 22, 2021 12:21:22 GMT -5
UTHR is dead serious about getting Tyvaso DPI to market as fast as possible. I can’t believe the market hasn’t recognized what a huge thing that is for MannKind. IMHO, the market will soon recognize that MannKind is becoming a force to be reckoned with. The development of Technosphere products is in its infancy. |
|
|
|
Post by olderteampt on Jan 22, 2021 14:07:29 GMT -5
To you point about MNKD becoming a force to be reckoned with:
1)Look at the problems they are having with the Covid-19 vaccines in terms of being ruined secondary to temperate requirements. If MNKD had combined with UTHR(or anyone else) they could have created a dry powder version that did not require refrigeration and needles to administer.
2)Also with the tensions building with China can you imagine how beneficial a dry powder version would be for our Military with the current Covid-19 threat and for any future new virus threats.
Side note: How beneficial for our Military would a SENS glucose monitor implant combined with a MNKD dry power inhaler be? Remember how AL Mann used to work with the Military???
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 22, 2021 14:12:50 GMT -5
UTHR is dead serious about getting Tyvaso DPI to market as fast as possible. I can’t believe the market hasn’t recognized what a huge thing that is for MannKind. IMHO, the market will soon recognize that MannKind is becoming a force to be reckoned with. The development of Technosphere products is in its infancy. Wall Street has been burned twice by MNKD. They are waiting until Approval is all but certain. |
|
|
|
Post by uvula on Jan 22, 2021 14:53:39 GMT -5
Our track record after approval isn't that good either.
|
|
|
|
Post by akemp3000 on Jan 22, 2021 15:12:21 GMT -5
I can think of 105 million reasons UTHR is convinced approval is not just likely but certain. They clearly have the data that supports it.
|
|
|
|
Post by centralcoastinvestor on Jan 22, 2021 15:19:10 GMT -5
I wonder what the share price will be when UTHR makes its first royalty payment to MannKind? Imagine a first payment of $20,000,000 or so. I am assuming Wall Street will be paying attention before that. But if they are not, that first royalty payment will be a very very big deal.
|
|
|
|
Post by cedafuntennis on Jan 22, 2021 15:29:50 GMT -5
There is no track record. 1 approval does not make a track. Also this is a totally different scenario. Not a small company going at it alone, an established product base with another delivery, a partner totally committed to this (unlike Sanofi who was committed all right, but committed to the destruction of Afreza and MNKD). I see this totally not in the same league.
|
|
|
|
Post by avi8torslc on Jan 22, 2021 16:44:28 GMT -5
That A hole still in prison.. This UTHR approval....
|
|
